Currently, monotherapy with zidovudine is recommended for:
A. Asymptomatic HIV positive subjects with
CD4 cell count more than 200/μl
B. Asymptomatic HIV positive subjects with
CD4 cell count less than 200/μl
C. HIV positive subjects with opportunistic
infection
D. None of the above
A. Asymptomatic HIV positive subjects with
CD4 cell count more than 200/μl
B. Asymptomatic HIV positive subjects with
CD4 cell count less than 200/μl
C. HIV positive subjects with opportunistic
infection
D. None of the above